MetLife Investment Management LLC Buys 652 Shares of Solventum Co. (NYSE:SOLV)

MetLife Investment Management LLC grew its stake in shares of Solventum Co. (NYSE:SOLV) by 1.8% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 36,583 shares of the company’s stock after acquiring an additional 652 shares during the period. MetLife Investment Management LLC’s holdings in Solventum were worth $2,417,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Modus Advisors LLC purchased a new stake in Solventum in the fourth quarter worth about $25,000. Stonebridge Financial Group LLC purchased a new position in Solventum during the fourth quarter valued at approximately $26,000. Crews Bank & Trust bought a new stake in Solventum during the 4th quarter valued at $32,000. Synergy Asset Management LLC purchased a new position in shares of Solventum in the 4th quarter valued at $35,000. Finally, Spire Wealth Management bought a new position in shares of Solventum in the 4th quarter worth $37,000.

Solventum Price Performance

Shares of SOLV opened at $66.14 on Monday. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $85.92. The stock has a market cap of $11.44 billion and a PE ratio of 24.05. The firm has a 50-day simple moving average of $72.58 and a two-hundred day simple moving average of $71.60. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83.

Analyst Ratings Changes

SOLV has been the subject of several research reports. Morgan Stanley lifted their price objective on shares of Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 5th. Piper Sandler increased their price objective on shares of Solventum from $75.00 to $84.00 and gave the company a “neutral” rating in a report on Friday, February 28th. The Goldman Sachs Group increased their price objective on shares of Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a report on Monday, March 3rd. Mizuho raised their price target on shares of Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a research note on Monday, March 3rd. Finally, Bank of America raised their price target on shares of Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 26th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $79.86.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.